Biden Administration Pause On Pending Trump-Era Rules Stalls FDA Cannabinoids Guidance Progress
Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.
You may also be interested in...
FDA’s tolerance of sales of hemp-containing supplements isn’t the assurance industry needs for investing in development of ingredients and products which have been shown to provide various health benefits.
FDA's evaluation of NDI notifications for cannabinoids currently is pointless, say industry stakeholders asking for a rule exempting hemp-derived cannabinoids from the agency’s prohibition against using in dietary supplements any ingredient studied or approved for use as a drug.
Appropriation Committee’s report with FDA’s FY2022 funding bill appears to signal that other than getting something done, members have little to say about establishing lawful use of hemp-derived cannabinoids in non-drug products.